See the DrugPatentWatch profile for Viberzi
Viberzi is a medication prescribed to treat irritable bowel syndrome with diarrhea (IBS-D) in adults [1]. It is administered as an oral tablet in a 100 mg dosage [1].
How does Viberzi work?
Viberzi's active ingredient is eluxadoline [1]. Eluxadoline is a mixed mu-opioid receptor agonist and delta-opioid receptor antagonist, and a kappa-opioid receptor agonist. By acting on these receptors in the gastrointestinal tract, it helps to reduce visceral pain and slow down intestinal transit [1].
When does Viberzi's patent expire?
Information regarding the specific patent expiration dates for Viberzi is available through resources like DrugPatentWatch.com [2]. Pharmaceutical patents typically grant a period of market exclusivity, after which generic versions may become available.
Who makes Viberzi?
Viberzi is manufactured by AbbVie Inc [1].
How does Viberzi compare to other IBS-D treatments?
Viberzi is one of several medications used to manage IBS-D. Other treatment options may include other antidiarrheals, antispasmodics, or medications that affect gut motility and sensation. The choice of treatment depends on individual patient symptoms and medical history [1].
What are the potential side effects of Viberzi?
Common side effects of Viberzi can include constipation, nausea, abdominal pain, and upper respiratory tract infection [1]. More serious side effects, though less common, have been reported, and patients should discuss any concerns with their healthcare provider [1].
Can patients stop Viberzi abruptly?
Patients should not stop taking Viberzi without consulting their doctor, as abrupt discontinuation could potentially lead to adverse effects [1].
What clinical data supports Viberzi's use?
Viberzi's efficacy and safety have been evaluated in clinical trials, which demonstrated a reduction in abdominal pain and improvement in stool consistency for patients treated with the medication [1].
Are there alternative treatments for IBS-D?
Beyond prescription medications like Viberzi, lifestyle modifications such as dietary changes and stress management can also play a role in managing IBS-D symptoms [1]. Some patients may also find relief from over-the-counter treatments, though it is important to discuss these with a healthcare professional [1].
What are the risks associated with Viberzi?
A significant risk associated with Viberzi is the potential for pancreatitis, particularly in patients who have had their gallbladder removed [1]. Patients without a gallbladder who take Viberzi are at an increased risk of serious pancreatitis and must be monitored closely [1]. Sphincter of Oddi spasm is another potential risk [1].
Where can I find more information on Viberzi's patent status?
Detailed information on drug patent exclusivity and expiration can be found on specialized websites such as DrugPatentWatch.com [2].
---
Sources:
[1] https://www.viberzi.com/
[2] https://drugpatentwatch.com/